Staging of brain pathology related to sporadic Parkinson’s disease

Braak, Heiko; Tredici, Kelly Del; Rüb, Udo; Vos, Rob A. I. de; Steur, Ernst N.H. Jansen; Braak, Eva

doi:10.1016/s0197-4580(02)00065-9

Cited by 8,830 publications

(8,388 citation statements)

References 58 publications

Supporting

382

Mentioning

7,504

Contrasting

Unclassified

198

Order By: Relevance

“…Lewy bodies were demonstrated by alpha synuclein immunohistochemistry in the brainstem, midbrain and limbic system (not shown). The extent of Lewy body disease was consistent with McKeith limbic category dementia with Lewy bodies (McKeith et al 1996), or Parkinson disease related Braak Stage IV (Braak et al 2003). There were also changes consistent with vascular dementia with moderate to severe atherosclerosis in the vessels at the base of the brain, which resulted in 50% stenosis of the left posterior cerebral artery and 75% stenosis of the left vertebral artery.…”

Section: Resultsmentioning

confidence: 53%

Clinical and pathological features of an Alzheimer's disease patient with the MAPT ΔK280 mutation

Momeni

Pittman²,

Lashley³

et al. 2009

Neurobiology of Aging

View full text Add to dashboard Cite

We identified a case of Alzheimer's disease with a deletion of the lysine residue at codon 280 (ΔK280) in exon 10-encoded microtubule-binding repeat domain of the tau gene (MAPT). This mutation was originally identified in a sporadic case of frontotemporal dementia (FTD) with a family history of Parkinson's disease. In the original report, the authors were careful in their assessment of the pathogenicity and suggested one could not be sure whether the mutation was pathogenic or not. The mutation has always presented a conundrum because it is the only known mutation, of assumed pathogenicity, which increases the proportion of 3-repeat tau mRNA in in vitro assays. Here we present the clinical and pathological features of a new case with this mutation and discuss whether the mutation is indeed pathogenic.

show abstract

Section: Resultsmentioning

confidence: 53%

Clinical and pathological features of an Alzheimer's disease patient with the MAPT ΔK280 mutation

Momeni

Pittman²,

Lashley³

et al. 2009

Neurobiology of Aging

View full text Add to dashboard Cite

show abstract

“…Parkinson's disease (PD) is characterized by the cardinal motor symptoms, such as bradykinesias, rigidity, postural instability, resting tremor, and nonmotor symptoms including psychiatric problems, autonomic disturbances, pain, fatigue and impaired cognition in executive functioning, memory and spatial behavior during the early stage of the disease (Chaudhuri & Odin, 2010; Vingerhoets, Verleden, Santens, Miatton, & De Reuck, 2003). The neuropathological hallmarks of PD include the loss of dopaminergic neurons in substantia nigra (SN) and the formation of neuronal protein inclusions known as Lewy bodies (LB) (Braak et al., 2003). Currently, all the therapeutics for PD only reduce the symptoms.…”

Section: Introductionmentioning

confidence: 99%

Identification of aberrant circulating miRNAs in Parkinson's disease plasma samples

Chen

Yang²,

et al. 2018

Brain and Behavior

View full text Add to dashboard Cite

ObjectiveTo detect the aberrant expression of circulating miRNAs and explore the potential early diagnostic biomarkers in patients with Parkinson's disease (PD).MethodsPlasma samples were collected from 25 treatment‐naïve PD‐diagnosed patients and 25 healthy controls followed by a real‐time PCR‐based miRNA screening analysis of neuron disease‐related miRNAs.ResultsA subset of miRNAs with aberrant expression levels in the plasma of PD‐diagnosed patients were identified including upregulation of miR‐27a and downregulation of let‐7a, let‐7f, miR‐142‐3p, and miR‐222 with the AUC values more than 0.8 derived from the receiver operating characteristic curves.ConclusionsThe high sensitivity and specificity of the circulating miRNAs may enable early diagnosis of PD. The study provides a group of novel miRNA candidates for detecting PD.

show abstract

“…In PD, degeneration of the olfactory nucleus with impairment of smell starts early in Braak stageI(Braak et al., 2003) and was thought to be specific for Lewy body‐type neurodegeneration. The PD ‐Parkin patients had less extensive distribution of Lewy bodies neuropathology, that might not follow Braak staging and spares olfactory structures (Doherty et al., 2013; Gouider‐Khouja et al., 2003), and might explain their preserved olfaction.…”

Section: Discussionmentioning

confidence: 99%

Olfaction in Parkin carriers in Chinese patients with Parkinson disease

Wang

Liu

et al. 2017

Brain and Behavior

View full text Add to dashboard Cite

BackgroundOlfactory identification was reported to be better among PD (Parkinson disease) patients with Parkin mutations, but previous studies didn't eliminate the interference of other PD related genes on olfaction, and whether olfaction of Parkin mutations patients was better in Chinese population was still unknown.ObjectiveTo assess olfaction function among PD patients with Parkin mutations in Chinese population.Materials and MethodsA total of 226 PD patients with a positive family history or an early‐onset age (<50 years) were enrolled for genetic testing of PD related genes by target sequencing and multiple ligation‐dependent probe amplification. The clinical data including olfactory function test were investigated. Linear regression was performed to adjust for the covariates between all groups.ResultsThere were 68 patients found having a negative result in PD genetic testing and 43 patients carrying homozygous or compound heterozygous Parkin mutations. Among them, 49 PD panel negative patients and 33 PD‐Parkin patients had results of olfactory assessment. PD ‐Parkin patients performed significantly better on the Sniffin’ Sticks tests than panel negative patients (8.0 ± 1.7 vs. 5.7 ± 1.9, p < .001), but still worse compared to healthy controls (9.4 ± 1.5, p = .003). These differences persisted after adjusting for confounders.ConclusionsAmong Chinese population, PD ‐Parkin patients had relatively preserved olfaction compared to PD panel negative patients after eliminating the interference of other PD related genes, but were still worse than healthy controls.

show abstract

Staging of brain pathology related to sporadic Parkinson’s disease

Cited by 8,830 publications

References 58 publications

Clinical and pathological features of an Alzheimer's disease patient with the MAPT ΔK280 mutation

Clinical and pathological features of an Alzheimer's disease patient with the MAPT ΔK280 mutation

Identification of aberrant circulating miRNAs in Parkinson's disease plasma samples

Olfaction in Parkin carriers in Chinese patients with Parkinson disease

Contact Info

Product

Resources

About